Firstmed Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 8.15%
- Profit Growth 16.89%
- Ebitda 35.23%
- Net Worth 26.73%
- Total Assets 15.16%
About Firstmed Therapeutics
Firstmed Therapeutics Private Limited (FTPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 October 2012 and has a history of 12 years and three months. Its registered office is in Pondicherry, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ramakrishnan and Manimegalai serve as directors at the Company.
Company Details
-
Location
Pondicherry, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TN2012PTC136229
-
Company No.
002748
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Oct 2012
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Firstmed Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramakrishnan
|
Director | 11-Jun-2024 | Current |
|
Manimegalai
|
Director | 11-Jun-2024 | Current |
Financial Performance of Firstmed Therapeutics.
Firstmed Therapeutics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.15% increase. The company also saw a substantial improvement in profitability, with a 16.89% increase in profit. The company's net worth Soared by an impressive increase of 26.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Firstmed Therapeutics?
In 2023, Firstmed Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Zeta Formulation Private LimitedRamakrishnan is a mutual person
-
Curio Pharmaceuticals Private Limited
Ramakrishnan and Manimegalai are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Firstmed Therapeutics?
Firstmed Therapeutics has a workforce of 23 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Firstmed Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Firstmed Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
